About VBI Vaccines (TSE:VBV)
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus. It is also developing congenital cytomegalovirus vaccine candidate for infectious disease; and therapeutic glioblastoma multiforme vaccine candidate for immuno-oncology. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts. VBI Vaccines Inc. is a subsidiary of FDS Pharma ASS.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolTSE:VBV
CUSIPN/A
Phone+1-617-8303031
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-5,078.76%
Return on Equity-59.42%
Return on Assets-43.57%
Miscellaneous
EmployeesN/A
Outstanding Shares64,079,000
VBI Vaccines (TSE:VBV) Frequently Asked Questions
What is VBI Vaccines' stock symbol?
VBI Vaccines trades on the Toronto Stock Exchange (TSX) under the ticker symbol "VBV."
Who are some of VBI Vaccines' key competitors?
Some companies that are related to VBI Vaccines include Sherritt International (S), Trinidad Drilling (TDG), Pure Technologies (PUR), Cardinal Energy (CJ), Stornoway Diamond (SWY), Medical Facilities (DR), Roots (ROOT), Pengrowth Energy (PGF), Sierra Metals (SMT), Contrans Group (CSS), Melcor Developments (MRD), Sirius XM Canada (XSR), Morguard North American (MRG.UN), Sulliden Gold (SUE), Alterra Power (AXY), Golden Star Resources (GSC), Crocotta Energy (CTA) and Gluskin Sheff (GS).
Who are VBI Vaccines' key executives?
VBI Vaccines' management team includes the folowing people:
- Mr. Jeff R. Baxter, CEO, Pres & Director (Age 57)
- Dr. David Evander Anderson Ph.D., Chief Scientific Officer (Age 48)
- Ms. Athena Kartsaklis, Sr. VP of Fin., Principal Financial & Accounting Officer, Chief Compliance Officer (Age 53)
- Ms. Nell Beattie, Chief Bus. Officer (Age 30)
- Dr. Francisco Diaz-Mitoma M.D., Ph.D., Chief Medical Officer (Age 63)
Has VBI Vaccines been receiving favorable news coverage?
Media headlines about VBV stock have trended somewhat positive on Friday, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. VBI Vaccines earned a news impact score of 0.09 on Accern's scale. They also assigned press coverage about the company an impact score of 47.00 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
How do I buy shares of VBI Vaccines?
Shares of VBV and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is VBI Vaccines' stock price today?
One share of VBV stock can currently be purchased for approximately C$4.82.
How big of a company is VBI Vaccines?
VBI Vaccines has a market capitalization of C$253.84 million.
How can I contact VBI Vaccines?
VBI Vaccines' mailing address is 222 3rd St Ste 2241, CAMBRIDGE, MA 02142-1259, United States. The company can be reached via phone at +1-617-8303031.
MarketBeat Community Rating for VBI Vaccines (VBV)
MarketBeat's community ratings are surveys of what our community members think about VBI Vaccines and other stocks. Vote "Outperform" if you believe VBV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VBV will underperform the S&P 500 over the long term. You may vote once every thirty days.
VBI Vaccines (TSE:VBV) Analyst Ratings History
| Date | Brokerage | Action | Rating | Price Target | Details |
|---|
(Data available from 4/20/2016 forward)
VBI Vaccines (TSE:VBV) Earnings History and Estimates Chart
VBI Vaccines (TSE VBV) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/13/2017 | Q3 2017 | C($0.29) | C($0.30) | C$0.19 million | C$0.24 million | View | N/A |  |
| 7/31/2017 | Q2 2017 | C($0.28) | C($0.30) | C$0.18 million | C$0.46 million | View | N/A | |
| 3/24/2017 | Q4 2016 | | C($0.24) | | C$0.14 million | View | N/A | |
| 8/15/2016 | Q2 2016 | | C($0.30) | | C$0.11 million | View | N/A | |
| 11/16/2015 | Q3 2015 | | C($0.40) | | C$0.14 million | View | N/A | |
| 8/14/2015 | Q2 2015 | | C($0.40) | | | View | N/A | |
| 2/6/2015 | Q4 2014 | | C($0.40) | | | View | N/A | |
| 8/12/2014 | Q2 2014 | | C($0.40) | | | View | N/A | |
| 6/25/2014 | Q1 2014 | | C($1.20) | | | View | N/A | |
| 2/13/2014 | Q4 2013 | | C($0.40) | | | View | N/A | |
| 11/13/2013 | Q3 2013 | | C($0.40) | | | View | N/A | |
| 2/12/2013 | Q4 2012 | | C($0.40) | | | View | N/A | |
| 11/13/2012 | Q3 2012 | | C($0.68) | | | View | N/A | |
| 8/15/2012 | Q2 2012 | | C($0.36) | | | View | N/A | |
| 6/29/2012 | Q1 2012 | | C($0.80) | | | View | N/A | |
| 3/26/2012 | Q1 2010 | | C($0.40) | | | View | N/A | |
| 2/29/2012 | Q4 2011 | | C($0.56) | | | View | N/A | |
| 11/30/2011 | Q3 2011 | | C($0.68) | | | View | N/A | |
| 9/28/2011 | Q2 2011 | | C($0.88) | | | View | N/A | |
| 7/28/2011 | Q1 2011 | | C($5.48) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
VBI Vaccines (TSE:VBV) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
VBI Vaccines (TSE VBV) Insider Trading and Institutional Ownership History
VBI Vaccines (TSE VBV) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/12/2017 | Jeffrey Royston Baxter | Director | Buy | 4,609 | C$3.88 | C$17,882.92 | | |
| 11/28/2017 | Jeffrey Royston Baxter | Director | Buy | 15,000 | C$4.75 | C$71,250.00 | | |
| 8/21/2017 | Francisco Diaz-Mitoma | Insider | Buy | 3,000 | C$3.17 | C$9,510.00 | | |
| 8/21/2017 | Jeffrey Royston Baxter | Director | Buy | 10,000 | C$3.22 | C$32,200.00 | | |
(Data available from 1/1/2013 forward)
VBI Vaccines (TSE VBV) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | VBI Vaccines (VBIV) Announces Exit of Sam Chawla and Ran Nussbaum from Board
www.streetinsider.com - January 27 at 9:29 AM |
 | VBI Vaccines Announces Changes to its Board of Directors
finance.yahoo.com - January 26 at 4:27 PM |
| VBI Vaccines, Inc. breached its 50 day moving average in a Bullish Manner : VBV-CA : January 1, 2018
finance.yahoo.com - January 1 at 8:12 AM |
| VBI Vaccines Announces Initiation of Phase 3 Clinical Program for Sci-B-Vac® Hepatitis B Vaccine
finance.yahoo.com - December 19 at 8:08 AM |
 | Jeffrey Royston Baxter Buys 4,609 Shares of VBI Vaccines Inc (VBV) Stock
www.americanbankingnews.com - December 13 at 10:20 PM |
| VBI Vaccines, Inc. breached its 50 day moving average in a Bearish Manner : VBV-CA : December 12, 2017
finance.yahoo.com - December 12 at 7:18 PM |
| VBI Vaccines to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference
finance.yahoo.com - December 12 at 8:06 AM |
| VBI Vaccines, Inc. :VBV-CA: Earnings Analysis: Q3, 2017 By the Numbers : November 16, 2017
finance.yahoo.com - November 30 at 4:41 PM |
| ETFs with exposure to VBI Vaccines, Inc. : November 27, 2017
finance.yahoo.com - November 30 at 4:41 PM |
| VBI Vaccines Inc. (VBV) Director Buys C$71,250.00 in Stock
www.americanbankingnews.com - November 29 at 10:40 PM |
| Insider Buying: VBI Vaccines Inc (VBV) Director Acquires 10,000 Shares of Stock
www.americanbankingnews.com - August 23 at 8:50 PM |
VBI Vaccines (TSE:VBV) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
VBI Vaccines (TSE VBV) Stock Chart for Friday, April, 20, 2018
Loading chart…
